Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Celsion Corporation (Note: The input metadata lists "Imunon, Inc.", but the filing text explicitly identifies the registrant as Celsion Corporation). The report covers the quarterly and six-month periods ended March 31, 2001. Celsion is a biotechnology company focused on developing thermotherapy systems for cancer treatment. The company has not yet achieved profitability and relies on equity financing to fund operations and clinical trials.
Key Financial Metrics
| Metric | Six Months Ended Mar 31, 2001 | Six Months Ended Mar 31, 2000 |
|---|---|---|
| Total Revenue | $1,858 | $3,465 |
| Gross Profit | $1,858 | $3,465 |
| Net Loss | $(2,953,008) | $(1,917,199) |
| Operating Expenses | $3,162,272 | $1,988,606 |
| Cash and Cash Equivalents (Mar 31, 2001) | $6,132,250 | $8,820,196 (Sep 30, 2000) |
| Working Capital | $6,157,018 | $8,509,173 (Sep 30, 2000) |
| Accumulated Deficit | $(29,586,804) | $(26,447,417) (Sep 30, 2000) |
| Net Cash Used in Operating Activities | $(2,728,294) | $(2,044,604) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 46% to $1,858 for the six months ended March 31, 2001, compared to $3,465 in the prior year. This is attributed to the discontinuation of marketing older thermotherapy systems and a lack of regulatory approval for new products.
- Increased Operating Expenses: Total operating expenses rose 59% to $3.16 million.
- General & Administrative (G&A): Increased 55% to $1.91 million due to higher staff, consulting, legal fees, and office expansion costs.
- Research & Development (R&D): Increased 65% to $1.25 million, driven by engineering costs for new BPH and breast cancer treatment equipment.
- Widening Loss: The net loss increased by 54% to $2.95 million for the six-month period.
- Cash Burn: Cash and cash equivalents decreased by approximately $2.69 million during the six-month period, primarily due to operating losses.
Guidance, Outlook, and Risks
- Outlook: Management expects operating losses to continue and possibly increase in the near term. No significant new product revenue is anticipated until new equipment receives regulatory approval. Current products are in pivotal Phase II clinical testing.
- Capital Requirements: The company estimates total expenditures of approximately $7 million for fiscal year 2001. It expects to meet these needs with current resources but acknowledges a continued dependence on raising additional capital.
- Risks:
- Funding: The company has no committed sources of additional financing. Failure to secure funds could force delays in operations or the relinquishment of technology rights.
- Regulatory: Profitability depends on obtaining governmental approvals for new technologies.
- Legal Proceedings: The company is involved in litigation against a former director and associates regarding the rescission of warrants for approximately 3.4 million shares. The case was transferred to the Northern District of Illinois.
- Unusual Items: The company issued 11.4 million shares of common stock upon conversion of Series A Convertible Preferred Stock and raised $115,000 from the exercise of stock options and warrants during the quarter.
Investor Verification Checklist
- Verify the status and timeline of the pivotal Phase II clinical trials for the breast cancer and BPH treatment systems.
- Confirm the company's ability to fund the estimated $7 million fiscal year 2001 budget without immediate dilution or debt financing.
- Monitor the outcome of the litigation against Warren C. Stearns regarding the 3.4 million share warrants.
- Assess the timeline for regulatory approvals required to generate significant revenue from new products.
- Review the burn rate of cash ($2.73 million over six months) against current cash reserves ($6.13 million) to estimate runway.